AIMTo present the current state-of-the art of molecular imaging in the management of patients affected by inflammatory bowel disease (IBD).METHODSA systematic review of the literature was performed in order to find important original articles on the role of molecular imaging in the management of patients affected by IBD. The search was updated until February 2016 and limited to articles in English.RESULTSFifty-five original articles were included in this review, highlighting the role of single photon emission tomography and positron emission tomography.CONCLUSIONTo date, molecular imaging represents a useful tool to detect active disease in IBD. However, the available data need to be validated in prospective multicenter studies on larger patient samples.
Aim
18F-Fluorodeoxyglucose (FDG) PET imaging may play an important role in the restaging of patients with small-cell lung cancer (SCLC),, nevertheless, a systematic review of literature was still missing in this setting. The aim of this review was to summarize the evidence on literature regarding the utility of 18F-FDG PET imaging in restaging patients with SCLC.
Methods
A literature search was performed to retrieve original studies using 18F-FDG PET or 18F-FDG PET/computed tomography (CT) in a minimum of 10 patients with SCLC at restaging.
Results
The selected literature (17 studies) was discussed in four sections: detection rate, impact on management, prediction of prognosis and evaluation of the response to therapy. According to the literature, PET imaging may result in discordance with conventional imaging, mainly contrast-enhanced CT (ceCT), and detect additional lesions in a certain proportion of cases, leading to upstaging or downstaging. A variable level of disagreement between PET and conventional imaging has been reported also in the evaluation of response to therapy. A positive PET study is associated with shorter survival, especially in the presence of distant metastases. According to some studies, semiquantitative parameters are also inversely associated with overall survival and progression-free survival. Although the retrieved articles proved the utility of 18F-FDG PET imaging in each clinical setting, literature is still limited.
Conclusions
This review encourages the use of 18F-FDG PET imaging, especially in conjunction with ceCT in recurrent SCLC patients. Further level I evidence is needed to further assess the diagnostic and prognostic capability of 18F-FDG PET/ceCT findings in SCLC.
Hibernoma is a benign tumor arising from brown fat tissue. Conventional imaging techniques are not able to differentiate it from other benign lesions or malignant fatty tumors. We report the case of a 73-year-old patient who underwent a thorax computed tomography (CT) and was then referred to our department for metabolic assessment of a solitary lung nodule. An F18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) scan was performed and demonstrated, in addition, a highly metabolic fat-containing lesion mimicking a malignant fatty tumor in the left great pectoralis muscle. The lesion was excised and resulted to be a hibernoma. This case shows that hibernoma can appear as a malignant-like lesion on 18F-FDG-PET/CT scan as per other imaging techniques, and the grade of FDG uptake does not accurately reflect malignancy in this fat-containing tumor. However, 18F-FDG-PET/CT with its whole-body scanning capability may represent a useful imaging tool in identifying, in the course of an imaging study for oncological evaluation, additional incidental findings such as benign fat-containing lesions that may require a surgical approach.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.